The following is from Gallup News. Less than one-third of Americans, 29%, have gotten the new Covid-19 vaccine that was released this fall. In contrast, 47% of U.S. adults say they have gotten the annual flu shot this year. Another […]
(GALLUP) 29% have gotten latest ineffective Covid shot; 47% have gotten annual flu shot Read More »
The Biden administration is expected to recommend all Americans get a Covid-19 booster shot this fall, according to a White House official. The following is from Reuters. The Biden administration plans to urge all Americans to get a booster shot for the
White House says all Americans should get boosted against Covid-19 this fall Read More »
The following is a statement from the Centers for Disease Control and Prevention (CDC). CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe
CDC recommends new RSV vaccine for all infants under 8 months Read More »
The following is from The Vaccine Reaction. On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to
12 infant deaths reported in clinical trials for FDA-endorsed RSV drug Read More »
The following is from MedPage, which is supported by the pharmaceutical industry. An FDA advisory committee on Thursday gave strong backing to use of a monoclonal antibody against respiratory syncytial virus (RSV) to prevent lower respiratory tract disease (LRTD) in
FDA panel endorses monoclonal antibodies to prevent viral infection in infants Read More »
The following is an excerpt from Time. Pfizer Inc.’s vaccine to protect newborns from RSV received backing from U.S. regulatory advisers for use in pregnant mothers to protect their newborns, handing the drugmaker a win in the race to dominate
The following is an excerpt from Medpage Today. The FDA has approved the first-ever vaccine for respiratory syncytial virus (RSV) the agency announced on Wednesday. Marketed under the trade name of Arexvy, the adjuvanted RSV prefusion F protein-based vaccine is specifically
FDA green lights first-ever RSV vaccine for adults 60+ Read More »
The CDC is reporting a return to the usual when it comes to the virus that causes common colds. According to a news release today, Respiratory Syncytial Virus (RSV) is returning to the patterns seen prior to Covid-19. Recently, the
CDC: Common cold virus returns to pre-Covid patterns Read More »
